Viveve Neo: Relaunch

Viveve Relaunches with Viveve Neo™ — Continuing Our Mission, Embracing a New Chapter

The Viveve PURSUIT Trial is a pivotal U.S. Stress Urinary Incontinence trial that has completed all subject 12-month follow-up visits

Topline results of primary efficacy endpoint planned in January 2023.

Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Pivotal U.S. Investigational Device Exemption (IDE) cleared trial

PURSUIT is a randomized, double-blinded, sham-controlled, IDE-cleared trial that enrolled 415 subjects with moderate SUI at approximately 30 study sites in the United States. Subjects were randomized in a 2:1 ratio to the active Viveve treatment or an inert sham treatment.

Viveve aspires to be the leader in the treatment of female Stress Urinary Incontinence

The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency (CMRF) technology to uniformly provide an endovaginal treatment that is non-ablative.